ROCKVILLE, MD, Nov. 06, 2024 (GLOBE NEWSWIRE) — MacroGenics, Inc. MGNX, a biopharmaceutical firm centered on growing, manufacturing and commercializing progressive monoclonal antibody-based therapeutics for the therapy of most cancers, at present introduced that the Firm’s administration will take part within the following investor conferences this month:
- Guggenheim Securities Healthcare Innovation Convention (Boston). MacroGenics’ Chief Working Officer, Eric Risser, will take part in a hearth chat on Tuesday, November 12, 2024, at 4:00pm ET. MacroGenics’ administration can even take part in one-on-one conferences.
- Stifel 2024 Healthcare Convention (New York). MacroGenics’ President & Chief Govt Officer, Scott Koenig, M.D., Ph.D., will take part in a hearth chat on Monday, November 18, 2024, at 1:15pm ET. MacroGenics’ administration can even take part in one-on-one conferences.
Webcasts of the above shows could also be accessed beneath “Occasions & Displays” within the Investor Relations part of MacroGenics’ web site at The Firm will preserve archived replays of those webcasts on its web site for 30 days.
About MacroGenics, Inc.
MacroGenics (the Firm) is a biopharmaceutical firm centered on growing, manufacturing and commercializing progressive monoclonal antibody-based therapeutics for the therapy of most cancers. The Firm generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based expertise platforms, which have applicability throughout broad therapeutic domains. The mix of MacroGenics’ expertise platforms and protein engineering experience has allowed the Firm to generate promising product candidates and enter into a number of strategic collaborations with world pharmaceutical and biotechnology corporations. For extra info, please see the Firm’s web site at www.macrogenics.com. MacroGenics and the MacroGenics brand are logos or registered logos of MacroGenics, Inc.
###
CONTACTS: Jim Karrels, Senior Vice President, CFO 1-301-251-5172, [email protected]
Market Information and Information dropped at you by Benzinga APIs
© 2024 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
